8-K: Calidi Biotherapeutics Closes $6.9M Public Offering

Calidi Biotherapeutics successfully closed a $6.9 million underwritten public offering, including the full exercise of the underwriters' over-allotment option, to fund working capital and clinical trials.

Summary

• Calidi Biotherapeutics completed an underwritten public offering, raising gross proceeds of approximately $6.9 million.
• The offering included 1,922,764 common stock units and 1,528,000 pre-funded warrant units.
• The common stock units were priced at $2.00 each, and pre-funded warrant units at $1.999 each.
• The underwriters fully exercised their over-allotment option, purchasing an additional 450,000 common stock units.
• Each common stock unit consisted of one share of common stock and one Series I warrant.
• Each pre-funded unit consisted of one pre-funded warrant and one Series I warrant.
• Series I warrants have an exercise price of $2.00 per share, are immediately exercisable, and expire five years from issuance.
• Pre-funded warrants are immediately exercisable and can be exercised at any time until exercised in full.
• The company issued Representatives Warrants to purchase up to 172,538 shares of Common Stock at an exercise price of $3.00, expiring August 20, 2030.
• Proceeds are intended for working capital, general corporate purposes, pre-clinical studies, and clinical trial preparation.
• The company, its directors, and executive officers are subject to lock-up agreements for 60 or 90 days, restricting the issuance or disposal of securities.

Sentiment

Score: 7

Explanation: The successful completion of a capital raise, especially with the full exercise of the over-allotment option and participation from existing and new investors, is a positive development for a clinical-stage biotech company. It provides crucial funding for ongoing operations and pipeline advancement. However, the dilution for existing shareholders and the inherent risks of clinical development temper the overall sentiment.

Positives

• Successfully raised $6.9 million in gross proceeds, indicating investor confidence despite difficult market conditions.
• Full exercise of the over-allotment option suggests strong demand for the offering.
• Participation from current shareholders, new investors, management, and board members demonstrates internal and external support.
• The capital infusion provides funding for working capital, general corporate purposes, pre-clinical studies, and clinical trial preparation, advancing the company's pipeline.
• Warrants are fixed-priced and do not contain variable price features, which can be more favorable for existing shareholders than variable-priced warrants.

Negatives

• The offering involves the issuance of new common stock and warrants, which will result in dilution for existing shareholders.
• Underwriting discounts and commissions, along with other offering expenses, will reduce the net proceeds received by the company.
• The exercise price of the Series I warrants ($2.00) is equal to the public offering price of the common stock units, potentially limiting upside for warrant holders if the stock price does not significantly increase.
• The Representatives Warrants have an exercise price of $3.00, which is higher than the public offering price, but still represents potential future dilution upon exercise.

Risks

• Risk that Calidi is not able to raise sufficient capital to support its current and anticipated clinical trials.
• Risk that early results of clinical trials do not necessarily predict final results and that clinical outcomes may materially change.
• Risk that Calidi may not receive FDA approval for some or all of its therapeutic candidates.
• Other risks and uncertainties are set forth in the Company's annual report on Form 10-K filed on March 31, 2025.

Future Outlook

The company intends to use the proceeds from the offering for working capital, general corporate purposes, pre-clinical studies, and clinical trial preparation. It continues to advance its Redtail platform, with a lead candidate in IND-enabling studies targeting non-small cell lung cancer, ovarian cancer, and other tumor types, and is also developing clinical-stage protected virotherapies for localized administration.

Management Comments

• "We are extremely pleased to have priced this transaction despite difficult market conditions." Eric Poma, Chief Executive Officer of Calidi Biotherapeutics.
• "This transaction included participation from current shareholders and new investors as well as management and board members." Eric Poma, Chief Executive Officer of Calidi Biotherapeutics.

Industry Context

Calidi Biotherapeutics operates in the highly competitive and capital-intensive immuno-oncology and biotechnology sectors, focusing on targeted therapies using engineered oncolytic viruses. The successful capital raise, even in "difficult market conditions," suggests a degree of investor confidence in its Redtail platform and clinical pipeline, which aims to address high unmet medical needs in cancers like non-small cell lung cancer and ovarian cancer. This funding is crucial for advancing pre-clinical and clinical development in an industry where sustained R&D investment is paramount for product commercialization.

Comparison to Industry Standards

• The successful completion of an underwritten public offering, especially with the full exercise of an over-allotment option, is generally a positive indicator of market demand and investor confidence, comparable to successful capital raises by other clinical-stage biotech companies like Oncorus (ONCR) or Replimune (REPL) in their early development phases.
• The pricing of units at $2.00 and $1.999, with warrants at a $2.00 exercise price, is typical for offerings designed to attract a broad investor base, similar to recent offerings by smaller-cap biotech firms seeking to fund ongoing clinical trials.
• The use of proceeds for working capital, pre-clinical studies, and clinical trial preparation aligns with standard practices for clinical-stage biotechnology companies, such as those seen with companies like Kura Oncology (KURA) or Mirati Therapeutics (MRTX) in their early-to-mid-stage development.
• The lock-up agreements for management and the company (60-90 days) are standard practice in underwritten offerings to stabilize the stock price post-offering, similar to those implemented by companies like BridgeBio Pharma (BBIO) or Denali Therapeutics (DNLI) after their public offerings.

Corporate Governance

Stakeholder Impact

• Shareholders: Existing shareholders will experience dilution due to the issuance of new common stock and warrants. However, the capital raise provides funding for the company's operations and pipeline, which could lead to long-term value creation if successful.
• Investors (New & Existing): New investors and participating existing shareholders gain exposure to Calidi Biotherapeutics' pipeline at the offering price, with warrants providing additional upside potential.
• Employees: The capital infusion secures funding for ongoing operations, potentially ensuring job stability and continued progress on research and development.
• Creditors: A stronger cash position from the capital raise improves the company's financial stability, potentially reducing credit risk.

Next Steps

• Use proceeds for working capital and general corporate purposes.
• Advance pre-clinical studies and clinical trial preparation for the Redtail platform lead candidate.
• Continue development of clinical-stage protected virotherapies for intratumoral and localized administration.
• File the final executed Underwriting Agreement and Warrant Agency Agreement in the Form 10-Q for the quarter ended September 30, 2025.

Key Dates

Recommendation

The successful capital raise is a positive for Calidi Biotherapeutics, providing essential funding for its clinical programs and operations. The full exercise of the over-allotment option and insider participation indicate some confidence. However, as a clinical-stage biotech, significant risks remain regarding clinical trial outcomes, regulatory approvals, and the need for future capital. The dilution from the offering is a short-term negative. Given the funding secured and the long-term nature of biotech development, a "hold" recommendation is appropriate for investors who are already invested or considering a position, acknowledging both the progress and the inherent risks.

Keywords

Calidi Biotherapeutics, CLDI, public offering, underwritten offering, common stock units, pre-funded warrant units, Series I warrant, Redtail platform, immuno-oncology, clinical-stage, biotechnology, genetic medicines, oncolytic virus, non-small cell lung cancer, ovarian cancer, capital raise, SEC filing, 8-K